



Application No.: 09/234,028

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An substitute computer readable form (CRF) copy of the "Sequence Listing".
- An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

## Raw Sequence Listing Error Summary

### ERROR DETECTED   SUGGESTED CORRECTION

SERIAL NUMBER: 09/234,028A

**ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE**

1  Wrapped Nucleic  
The number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".

2  Wrapped Aminos  
The amino acid number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".

3  Incorrect Line Length  
The rules require that a line not exceed 72 characters in length. This includes spaces.

4  Misaligned Amino Acid Numbering  
The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.

5  Non-ASCII  
This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.  
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.

6  Variable Length  
Sequence(s)  contain n's or Xaa's which represented more than one residue.  
As per the rules, each n or Xaa can only represent a single residue.  
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.

7  PatentIn ver. 2.0 "bug"  
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)  . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.

8  Skipped Sequences (OLD RULES)  
Sequence(s)  missing. If intentional, please use the following format for each skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X:  
(I) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  
This sequence is intentionally skipped  
  
Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).

9  Skipped Sequences (NEW RULES)  
Sequence(s)  missing. If intentional, please use the following format for each skipped sequence:  
<210> sequence id number  
<400> sequence id number  
000

10  Use of n's or Xaa's (NEW RULES)  
Use of n's and/or Xaa's have been detected in the Sequence Listing.  
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

11  Use of <213>Organism (NEW RULES)  
Sequence(s)  are missing this mandatory field or its response.

12  Use of <220>Feature (NEW RULES)  
Sequence(s)  are missing the <220>Feature and associated headings.  
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"  
Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)

13  PatentIn ver. 2.0 "bug"  
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other means to copy file to floppy disk.

AKS-Biotechnology Systems Branch- 5/15/99

1653

PAGE: 1

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/234,028ADATE: 05/25/1999  
TIME: 14:14:43

Input Set: I234028A.RAW

This Raw Listing contains the General Information Section and those Sequences containing ERRORS.

E--> 1 <110> > See item 13 on Error Summary Sheet  
 E--> 2 <120> for explanation of missing mandatory  
 W--> 3 <130> item, if file was created  
 4 <140> US/09/234,028A *Does Not Comply*  
 5 <141> 1999-01-20 *Connected Diskette Needed*  
 E--> 6 <160> Item 13 *in Patent In 2.0*

## ERRORED SEQUENCES FOLLOW

E--> 7 <210> 2  
 8 <211> 456  
 9 <212> PRT  
 10 <213> Sus sp.  
 11 <400> 2  
 12 Met Asn Leu Asp Ile His Cys Glu Gln Leu Ser Asp Ala Arg Trp Thr  
 13 1 5 10 15  
 14 Glu Leu Leu Pro Leu Leu Gln Gln Tyr Glu Val Val Arg Leu Asp Asp  
 15 20 25 30  
 16 Cys Gly Leu Thr Glu Glu His Cys Lys Asp Ile Gly Ser Ala Leu Arg  
 17 35 40 45  
 18 Ala Asn Pro Ser Leu Thr Glu Leu Cys Leu Arg Thr Asn Glu Leu Gly  
 19 50 55 60  
 20 Asp Ala Gly Val His Leu Val Leu Gln Gly Leu Gln Ser Pro Thr Cys  
 21 65 70 75 80  
 22 Lys Ile Gln Lys Leu Ser Leu Gln Asn Cys Ser Leu Thr Glu Ala Gly  
 23 85 90 95  
 24 Cys Gly Val Leu Pro Ser Thr Leu Arg Ser Leu Pro Thr Leu Arg Glu  
 25 100 105 110  
 26 Leu His Leu Ser Asp Asn Pro Leu Gly Asp Ala Gly Leu Arg Leu Leu  
 27 115 120 125  
 28 Cys Glu Gly Leu Leu Asp Pro Gln Cys His Leu Glu Lys Leu Gln Leu  
 29 130 135 140  
 30 Glu Tyr Cys Arg Leu Thr Ala Ala Ser Cys Glu Pro Leu Ala Ser Val  
 31 145 150 155 160  
 32 Leu Arg Ala Thr Arg Ala Leu Lys Glu Leu Thr Val Ser Asn Asn Asp  
 33 165 170 175  
 34 Ile Gly Glu Ala Gly Ala Arg Val Leu Gly Gln Gly Leu Ala Asp Ser  
 35 180 185 190  
 36 Ala Cys Gln Leu Glu Thr Leu Arg Leu Glu Asn Cys Gly Leu Thr Pro  
 37 195 200 205  
 38 Ala Asn Cys Lys Asp Leu Cys Gly Ile Val Ala Ser Gln Ala Ser Leu  
 39 210 215 220

FUYI

Please review the  
Sequence Listing to ensure that a corresponding explanation is presented in the <220> |  
<223> fields for each sequence which presents at least one n or Xaa.

delete - not used under new Sequence Rule

## SEQUENCE LISTING

<210> 1 <Please insert  
 <211> ~~the mandatory~~  
 <212> PRT  
 <213> Rattus sp. ~~numerous identifiers and their responses~~

<400> 1  
 Met Ser Leu Asp Ile Gln Cys Glu Gln Leu Ser Asp Ala Arg Trp Thr  
 1 5 10 15  
 Glu Leu Leu Pro Leu Ile Gln Gln Tyr Gln Val Val Arg Leu Asp Asp  
 20 25 30  
 Cys Gly Leu Thr Glu Val Arg Cys Lys Asp Ile Arg Ser Ala Ile Gln  
 35 40 45  
 Ala Asn Pro Ala Leu Thr Glu Leu Ser Leu Arg Thr Asn Glu Leu Gly  
 50 55 60  
 Asp Ala Gly Val Gly Leu Val Leu Gln Gly Leu Gln Asn Pro Thr Cys  
 65 70 75 80  
 Lys Ile Gln Lys Leu Ser Leu Gln Asn Cys Ser Leu Thr Glu Ala Gly  
 85 90 95  
 Cys Gly Val Leu Pro Asp Val Leu Arg Ser Leu Ser Thr Leu Arg Glu  
 100 105 110  
 Leu His Leu Asn Asp Asn Pro Leu Gly Asp Glu Gly Leu Lys Leu Leu  
 115 120 125  
 Cys Glu Gly Leu Arg Asp Pro Gln Cys Arg Leu Glu Lys Leu Gln Leu  
 130 135 140  
 Glu Tyr Cys Asn Leu Thr Ala Thr Ser Cys Glu Pro Leu Ala Ser Val  
 145 150 155 160  
 Leu Arg Val Lys Pro Asp Phe Lys Glu Leu Val Leu Ser Asn Asn Asp  
 165 170 175  
 Phe His Glu Ala Gly Ile His Thr Leu Cys Gln Gly Leu Lys Asp Ser  
 180 185 190  
 Ala Cys Gln Leu Glu Ser Leu Lys Leu Glu Asn Cys Gly Ile Thr Ser  
 195 200 205  
 Ala Asn Cys Lys Asp Leu Cys Asp Val Val Ala Ser Lys Ala Ser Leu  
 210 215 220  
 Gln Glu Leu Asp Leu Gly Ser Asn Lys Leu Gly Asn Thr Gly Ile Ala  
 225 230 235 240  
 Ala Leu Cys Ser Gly Leu Leu Leu Pro Ser Cys Arg Leu Arg Thr Leu  
 245 250 255  
 Trp Leu Trp Asp Cys Asp Val Thr Ala Glu Gly Cys Lys Asp Leu Cys  
 260 265 270  
 Arg Val Leu Arg Ala Lys Gln Ser Leu Lys Glu Leu Ser Leu Ala Gly  
 275 280 285  
 Asn Glu Leu Lys Asp Glu Gly Ala Gln Leu Leu Cys Glu Ser Leu Leu

290 295 300

Glu Pro Gly Cys Gln Leu Glu Ser Leu Trp Val Lys Thr Cys Ser Leu  
305 310 315 320

Thr Ala Ala Ser Cys Pro His Phe Cys Ser Val Leu Thr Lys Asn Ser  
325 330 335

Ser Leu Phe Glu Leu Gln Met Ser Ser Asn Pro Leu Gly Asp Ser Gly  
340 345 350

Val Val Glu Leu Cys Lys Ala Leu Gly Tyr Pro Asp Thr Val Leu Arg  
355 360 365

Val Leu Trp Leu Gly Asp Cys Asp Val Thr Asp Ser Gly Cys Ser Ser  
370 375 380

Leu Ala Thr Val Leu Leu Ala Asn Arg Ser Leu Arg Glu Leu Asp Leu  
385 390 395 400

Ser Asn Asn Cys Met Gly Asp Asn Gly Val Leu Gln Leu Leu Glu Ser  
405 410 415

Leu Lys Gln Pro Ser Cys Ile Leu Gln Gln Leu Val Leu Tyr Asp Ile  
420 425 430

Tyr Trp Thr Asp Glu Val Glu Asp Gln Leu Arg Ala Leu Glu Glu  
435 440 445

Arg Pro Ser Leu Arg Ile Ile Ser  
450 455